{"id":"NCT01438840","sponsor":"Eisai Inc.","briefTitle":"Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenia Purpura)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-02-16","primaryCompletion":"2013-11","completion":"2014-03","firstPosted":"2011-09-22","resultsPosted":"2018-01-05","lastUpdate":"2018-02-05"},"enrollment":49,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Thrombocytopenia","Immune Thrombocytopenia"],"interventions":[{"type":"DRUG","name":"Avatrombopag","otherNames":["E5501","Avatrombopag maleate"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Standard of care","otherNames":[]}],"arms":[{"label":"Avatrombopag (Core Study)","type":"ACTIVE_COMPARATOR"},{"label":"Placebo (Core Study)","type":"PLACEBO_COMPARATOR"},{"label":"Avatrombopag (Open-Label Extension)","type":"EXPERIMENTAL"}],"summary":"Core Study:\n\nTo demonstrate that the efficacy of avatrombopag (in addition to standard of care) is superior to placebo (in addition to standard of care) for the treatment of adult participants with chronic immune thrombocytopenia (idiopathic thrombocytopenic purpura) (ITP) as measured by cumulative number of weeks of platelet response over 6 months of once daily treatment in adults participants who received at least 1 prior ITP therapy.\n\nExtension Phase:\n\nTo evaluate the safety and tolerability of long-term therapy with avatrombopag in participants with chronic ITP (cITP).","primaryOutcome":{"measure":"Number of Weeks With Platelet Count Greater Than or Equal to 50 x 10^9/L During 6-Month Treatment Period","timeFrame":"Week 1 to Week 26","effectByArm":[{"arm":"Placebo (Core Study)","deltaMin":0,"sd":null},{"arm":"Avatrombopag (Core Study)","deltaMin":12.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":25,"countries":["Australia","Belgium","Bulgaria","Czechia","Netherlands","New Zealand","Poland","Singapore","Slovakia","South Africa","Ukraine"]},"refs":{"pmids":["30191972"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":17},"commonTop":["Contusion","Headache","Upper respiratory tract infection","Epistaxis","Gingival bleeding"]}}